From the Guidelines
Ganaton (itopride hydrochloride) tablets are typically prescribed at a dosage of 50 mg three times daily, taken before meals. The standard treatment regimen is 150 mg total daily dose, divided into three equal doses. For patients with severe gastrointestinal motility disorders, the dosage may occasionally be increased to 100 mg three times daily, but this should only be done under medical supervision. Treatment duration varies based on the condition being treated, but often continues for 4-8 weeks for functional dyspepsia. Ganaton works by enhancing gastrointestinal motility and has anti-emetic properties due to its dopamine D2 receptor antagonist and acetylcholinesterase inhibitory effects. This medication helps improve symptoms like bloating, early satiety, and upper abdominal discomfort. Patients should take the medication consistently at the prescribed times for optimal effect and should consult their healthcare provider before adjusting the dose or stopping treatment. Those with severe liver or kidney disease may require dosage adjustments 1.
From the FDA Drug Label
DOSAGE FORMS AND STRENGTHS Delayed-Release Tablets: 20 mg ( 3). The dosage of Ganaton (Itopride) tablets is 20 mg 2
From the Research
Dosage of Ganaton (Itopride) Tablets
The dosage of Ganaton (Itopride) tablets can be summarized as follows:
- 50 mg three times daily before meals for 4 weeks, as prescribed in a study published in 2011 3
- 50 mg or mosapride citrate 5 mg three times daily before meals for a period of 2 weeks, as administered in a study published in 2004 4
- 150 mg/day, as added to the PPI therapy in a study published in 2024 5
- 50 mg three times daily before meals for 8 weeks, as used in a study published in 2014 6
- 50mg three times daily, as compared to domperidone 10mg three times daily for two weeks in a study published in 2004 7
Key Findings
Some key findings related to the dosage of Ganaton (Itopride) tablets include:
- The treatment response rate after 4 weeks was measured by patient global assessment, with a mean reduction from baseline of 69.23% in a study published in 2011 3
- Global efficacy as judged by patients was excellent in 17 versus 9 (p < 0.05) and poor in 0 versus 3 (p < 0.05) in a study published in 2004 4
- The greatest improvement after the combined treatment (p < 0.001) was experienced in the context of heartburn, nausea and laryngopharyngeal symptoms in a study published in 2024 5
- The proportion of patients who achieved the therapeutic effect (86%) at week 8 was higher than the historical placebo controls in the previous studies--45% (86% vs 45%; X2 = 68.868, df = 3; p < 0.001) in a study published in 2014 6
- Moderate to complete symptomatic relief was observed in 22 (81%) patients in the itopride group and 19 patients (70%) in the domperidone group (p > 0.05, NS) in a study published in 2004 7